Drug intelligence / Profile preview

midazolam + ketamine

Development stage
Phase 3
Lead developer
Harrow
Modality
Small Molecules
Administration
Intravenous
01

Overview

The combination of midazolam and ketamine is used for procedural sedation and analgesia, particularly in emergency departments and minor surgical or diagnostic procedures. Midazolam is a benzodiazepine that provides anxiolysis, amnesia, and sedation by enhancing the effect of the neurotransmitter GABA at the GABA-A receptor. Ketamine is a dissociative anesthetic that acts primarily as an NMDA receptor antagonist, producing analgesia, anesthesia, and amnesia while maintaining airway reflexes. The combination leverages the sedative and anxiolytic effects of midazolam with the potent analgesic properties of ketamine. This pairing can reduce adverse emergence reactions associated with ketamine alone while providing effective pain control and sedation[1][2][3][4][5]. It is considered safe when administered under medical supervision but may increase risks such as respiratory depression or excessive sedation[8].

Brand names
Versed (for midazolam)Ketalar (for ketamine)
Other names
none
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on midazolam + ketamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on midazolam + ketamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call